The immune system comprises organs, tissues, cells and molecules, which protect the body against pathogens.
Detailed description
The biological defense system can be separated into an innate and an adaptive part. The innate immune system developed early in the phylogeny of living things. The adaptive immune system adjusts to new or modified pathogens. Both parts collaborate closely. Moreover, the immune system can destroy abnormal or defective cells of the own body.
Scientists at the Institute of Tropical Medicine of the University of Tübingen, the German Center for Infection Research (DZIF), and of Sanaria Inc. have developed an infection system that allows
The first joint study to be conducted across all twelve clinical trial units at the German Center for Infection Research (DZIF) has been initiated. The aim of the study is to improve vaccine
DZIF researchers from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) produced a molecule that provides a way to visualise Pseudomonas infection. The scientists published their
In the light of growing antibiotic resistance, developing alternative tuberculosis treatment approaches is of critical importance. Scientists at the Research Center Borstel and the DZIF have now shown
For over 20 years, Professor Andreas Peschel from the Interfaculty Institute of Microbiology and Infection Medicine Tübingen (IMIT) and the German Center for Infection Research (DZIF) has dedicated
The latest outbreaks of emerging, dangerous pathogens, such as Ebola, MERS-CoV or Zika, emphasise the importance of the rapid development of effective vaccines. However, being able to predict the
Chronic lung infections caused by the bacterium Pseudomonas aeruginosa require complex and, in most cases, long-term treatment with antibiotics. It is generally not possible to completely heal the
Some HIV-infected – and untreated children – who do not develop AIDS, control the virus in a different way from the few infected adults who remain disease-free. Dr Maximilian Muenchhoff, DZIF
Researchers at the ImmunoSensation cluster of excellence at the University of Bonn have managed to do what many scientists dream of: together with researchers from the USA, they have patented new
In 2016, a clinical phase I trial on a potential vaccine against the dreaded Ebola virus was successfully completed. The tested vaccine “rVSV-ZEBOV” proved to be safe and effective. In a further trial
